These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 10641779)

  • 21. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
    Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
    Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease.
    Provenzano R; Singh AK
    Endocr Pract; 2007; 13(3):251-9. PubMed ID: 17599856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease.
    Spinowitz B; Germain M; Benz R; Wolfson M; McGowan T; Tang KL; Kamin M;
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1015-21. PubMed ID: 18400964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients.
    Fang YW; Chang CH
    Perit Dial Int; 2009; 29(2):199-203. PubMed ID: 19293358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Erythropoietin with iron supplementation to prevent allogeneic blood transfusion in total hip joint arthroplasty. A randomized, controlled trial.
    Feagan BG; Wong CJ; Kirkley A; Johnston DW; Smith FC; Whitsitt P; Wheeler SL; Lau CY
    Ann Intern Med; 2000 Dec; 133(11):845-54. PubMed ID: 11103054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy.
    Cortesi E; Mancuso A; De Pasquale Ceratti A; Pizzardi N; D'Auria G; Accettura C; Beccaglia P; Bertelletti D; De Marinis F
    Oncologist; 2004; 9(4):459-68. PubMed ID: 15266099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
    Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients.
    Levine AM; Salvato P; Leitz GJ;
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):131-9. PubMed ID: 18284320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
    Kilpatrick RD; Critchlow CW; Fishbane S; Besarab A; Stehman-Breen C; Krishnan M; Bradbury BD
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1077-83. PubMed ID: 18417744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
    Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
    Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
    Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
    Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with successful epoetin alfa therapy in premature infants.
    Reiter PD; Rosenberg AA; Valuck RJ
    Ann Pharmacother; 2000 Apr; 34(4):433-9. PubMed ID: 10772426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.